Factors Affecting Quality of Life and Satisfaction in Patients with Arthritis after Change to a Fixed-Dose Naproxen/Esomeprazole Combination Drug|RISS 상세보기

다국어 초록 (Multilingual Abstract)

Background: In drug therapy for patients with arthritis, a naproxen/esomeprazole combination drug may be a tolerable choice because it can minimize gastrointestinal and cardiovascular adverse effects. The aim of this study was to investigate the changes in quality of life (QOL), medication adherence, and satisfaction after switch from the existing drug to the combination drug. In addition, we analyzed the correlation between the above-mentioned variables and the stratified demographic and medical data of the patients.
Methods: A prospective, noninterventional, observational study was conducted in 30 hospitals between May 2014 and July 2016. In total, 2,308 patients with osteoarthritis, 99 patients with rheumatoid arthritis, and 76 patients with ankylosing spondylitis were enrolled. Demographic information (age, sex, body mass index [BMI], alcohol consumption, and smoking) and medical information (type of arthritis, duration of disease, and comorbidities) were collected via a self-administered questionnaire. Patients were observed for more than three months after switching to the combination drug. Data on the QOL (EuroQoL 5-Dimension questionnaire [EQ-5D questionnaire]), medication adherence (Morisky Medication Adherence Scale [MMAS]), and satisfaction were collected at the first and last visits.
Results: A total of 2,483 patients enrolled at 30 hospitals completed the questionnaire. After the switch to the combination drug, the mean EQ-5D score improved from 0.72 ± 0.17 to 0.79 ± 0.14 (p < 0.001), and significant improvement was associated with female sex (p = 0.016), shorter disease duration (p < 0.001), and absence of comorbidities (p < 0.001). The mean MMAS score was 6.38 ± 1.77, indicating medium adherence. Satisfaction was significantly higher in female patients (p < 0.001), in patients with a shorter disease duration (p < 0.001), osteoarthritis (p = 0.003), and no comorbidities (p < 0.001). Serious drug-related adverse effects did not occur.
Conclusions: The overall QOL was improved with medium adherence after the switch to the combination drug. On the basis of the analysis of stratified data, sex, age, drinking, smoking, disease duration, comorbidities, and BMI might be associated with QOL, satisfaction, and adherence.

번역하기

참고문헌 (Reference)

1 Sturkenboom MC, "Underutilization of preventive strategies in patients receiving NSAIDs" 42 (42): ii23-ii31, 2003

2 Hee-Chun Kim, "The Pattern of Use of Oral NSAIDs with or without Coprescription of Gastroprotective Agent for Arthritic Knee by Korean Practitioners" 대한슬관절학회 23 (23): 203-207, 2011

3 Scheiman JM, "Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events" 32 (32): 667-677, 2010

4 Yeomans N, "Quality of life in chronic NSAID users : a comparison of the effect of omeprazole and misoprostol" 30 (30): 328-334, 2001

5 La Montagna G, "Quality of life assessment during six months of NSAID treatment [Gonarthrosis and Quality of Life(GOAL)Study]" 16 (16): 49-54, 1998

6 Eusebi LH, "Proton pump inhibitors : risks of long-term use" 32 (32): 1295-1302, 2017

7 Laine L, "Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines" 30 (30): 767-774, 2009

8 Morisky DE, "Predictive validity of a medication adherence measure in an outpatient setting" 10 (10): 348-354, 2008

9 Gabriel SE, "Patient preferences for nonsteroidal antiinflammatory drug related gastrointestinal complications and their prophylaxis" 20 (20): 358-361, 1993

10 Abraham NS, "National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs" 129 (129): 1171-1178, 2005